Welcome to LookChem.com Sign In|Join Free

CAS

  • or

256373-91-8

Post Buying Request

256373-91-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

256373-91-8 Usage

Description

ETHYL 5-(CHLOROSULFONYL)-3-FUROATE is a chemical compound that belongs to the class of sulfonates. It is a white to light yellow crystalline powder that is soluble in organic solvents and is known for its strong chlorosulfonylating properties, making it a valuable reagent in organic synthesis.

Uses

Used in Pharmaceutical Industry:
ETHYL 5-(CHLOROSULFONYL)-3-FUROATE is used as an intermediate in the synthesis of pharmaceuticals for its ability to facilitate the formation of various drug molecules.
Used in Agrochemical Industry:
ETHYL 5-(CHLOROSULFONYL)-3-FUROATE is used as an intermediate in the synthesis of agrochemicals, contributing to the development of effective pesticides and other agricultural products.
Used in Dye and Pigment Production:
ETHYL 5-(CHLOROSULFONYL)-3-FUROATE is used in the production of dyes and pigments, playing a role in creating a wide range of colors for various applications.
Used in Organic Synthesis:
ETHYL 5-(CHLOROSULFONYL)-3-FUROATE is used as a reagent in organic synthesis, taking advantage of its strong chlorosulfonylating properties to aid in the creation of diverse organic compounds.
It should be noted that due to its potentially hazardous nature, ETHYL 5-(CHLOROSULFONYL)-3-FUROATE should be handled with care.

Check Digit Verification of cas no

The CAS Registry Mumber 256373-91-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,6,3,7 and 3 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 256373-91:
(8*2)+(7*5)+(6*6)+(5*3)+(4*7)+(3*3)+(2*9)+(1*1)=158
158 % 10 = 8
So 256373-91-8 is a valid CAS Registry Number.

256373-91-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name ethyl 5-chlorosulfonylfuran-3-carboxylate

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:256373-91-8 SDS

256373-91-8Relevant articles and documents

Synthesis of deuterium-labelled analogues of NLRP3 inflammasome inhibitor MCC950

Salla, Manohar,Butler, Mark S.,Massey, Nicholas L.,Reid, Janet C.,Cooper, Matthew A.,Robertson, Avril A.B.

, p. 793 - 795 (2018)

This study describes the syntheses of di, tetra and hexa deuterated analogues of the NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome inhibitor MCC950. In di and tetra deuterated analogues, deuteriums were incorporated into the 1,2,3,5,6,7-hexahydro-s-indacene moiety, whereas in the hexa deuterated MCC950 deuteriums were incorporated into the 2-(furan-3-yl)propan-2-ol moiety. The di deuterated MCC950 analogue was synthesised from 4-amino-3,5,6,7-tetrahydro-s-indacen-1(2H)-one 5. Tetra deuterated analogues were synthesised in 10 chemical steps starting with 5-bromo-2,3-dihydro-1H-inden-1-one 9, whereas the hexa deuterated analogue was synthesised in four chemical steps starting with ethyl-3-furoate 24. All of the compounds exhibited similar activity to MCC950 (IC50 = 8 nM). These deuterated analogues are useful as internal standards in LC-MS analyses of biological samples from in vivo studies.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

-

Page/Page column 266-267, (2020/06/10)

In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Sulfonamide compound and medical applications thereof

-

Paragraph 0056; 0058; 0060, (2019/02/13)

The invention discloses a compound containing a sulfonamide structure, a preparation method thereof, and medical applications of the compound, and more specifically discloses the compound with a structure represented by formula I, and a pharmaceutically acceptable salt or a prodrug or a solvate thereof. The compound is used for tumor treatment through inhibiting ATP-citrate lyase.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 256373-91-8